Scrip
Neuromed's long-acting opioid Exalgo heads for US panel review
11 August 2009
Sue Sutter
Please Login to read the full article.
11 August 2009
Sue Sutter
The US FDA's anaesthetic and life support drugs advisory panel will review Neuromed Pharmaceuticals' extended-release opioid Exalgo (hydromorphone HCl) on September 23rd. The proposed indication is treatment of moderate to severe pain in opioid-tolerant patients.
Exalgo extended-release...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA approves CombinatoRx/Covidien's extended-release Exalgo for pain
- Opioid class REMS will not delay new drug approvals, FDA says
- Neuromed's extended-release hydromorphone successful in US Phase III trials
- FDA user fee date for Neuromed/Covidien's Exalgo pushed back to February
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
